Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss

Brain Research

Volumn 871, Issue 2, 2000, Pages 259-270

  Harvey, Dennis C ^a   Lacan, Goran ^a   Tanious, Simon P ^a   Melega, William P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Methamphetamine; Neurodegeneration; Neuronal plasticity; Neurotoxicity; Parkinson's disease; PET

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE TRANSPORTER; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; IMMUNOREACTIVITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MEDIAL FOREBRAIN BUNDLE; MESENCEPHALON; MONKEY; MONOAMINERGIC SYSTEM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; CARBON RADIOISOTOPES; CARRIER PROTEINS; CELL COUNT; CERCOPITHECUS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; NEOSTRIATUM; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; NEUROPEPTIDES; RECOVERY OF FUNCTION; SUBSTANTIA NIGRA; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TYROSINE 3-MONOOXYGENASE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0034698409     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02439-2     Document Type: Article

References (72)

1. K.J. Axt, L.A. Mamounas, M.E. Molliver, Structural features of amphetamine neurotoxicity in the brain, in: A.K. Cho, D.S. Segal (Eds.), Amphetamine and Its Analogs: Psychopharmacology, Toxicology, and Abuse, Academic Press, Inc, San Diego, CA, 1994, pp. 315-358.
2. A. Bjorklund, C. Rosenblad, C. Winkler, D. Kirik, Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease, Neurobiol. Disease 4 (1997) 186-200.
3. K. Bowenkamp, D. David, P. Lapchak, M. Henry, A. Granholm, B. Hoffer, T. Mahalik, 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat: a possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor, Exp. Brain Res. 111 (1996) 1-7.
4. J.F. Bowyer, R.R. Holson, Methamphetamine and amphetamine neurotoxicity, in: L.W. Chang, R.S. Dyer (Eds.), Handbook of Neurotoxicology, Marcel Dekker, Inc, New York, 1995, pp. 845-870.
5. J. Cadet, C. Brannock, Free radicals and the pathobiology of brain dopamine systems, Neurochem. Int. 32 (1998) 117-131.
6. W. Cass, M. Manning, Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine, J. Neurosci 19 (1999) 7653-7660.
7. J. Cubells, S. Rayport, G. Rajendran, D. Sulzer, Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress, J. Neurosci. 14 (1994) 2260-2271.
8. M. Eddleston, L. Mucke, Molecular profile of reactive astrocytes implications for their role in neurologic disease, Neuroscience 54 (1993) 15-36.
9. A. Eisch, J. Marshall, Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury, Synapse 30 (1998) 433-445.
10. A. Eisch, L. Schmued, J. Marshall, Characterizing cortical neuron injury with Fluoro-Jade labeling after a neurotoxic regimen of methamphetamine, Synapse 30 (1998) 329-333.
11. A. Emmi, H. Rajabi, J. Stewart, Behavioral and neurochemical recovery from partial 6-hydroxydopamine lesions of the substantia nigra is blocked by daily treatment with glutamate receptor antagonists MK-801 and CPP, J. Neurosci. 16 (1996) 5216-5224.
12. C. Fischer, G. Hatzidimitriou, J. Wlos, J. Katz, G. Ricaurte, Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug ( +/-)3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), J. Neurosci. 15 (1995) 5476-5485.
13. A. Fleckenstein, R. Metzger, D. Wilkins, J. Gibb, G. Hanson, Rapid and reversible effects of methamphetamine on dopamine transporters, J. Pharm. Exp. Therapeutics 262 (1997) 834-838.
14. A. Fleckenstein, D. Wilkins, J. Gibb, G. Hanson, Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration, J. Pharm. Exp. Therapeutics 283 (1997) 281-285.
15. J. Francis, J. Von Visger, G. Markelonis, T. Oh, Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum, Neurotoxicol. Teratol. 17 (1995) 7-12.
16. C. Francois, G. Percheron, J. Yelnik, S. Heyner, A histological atlas of the macaque (Macaca mulatta) substantia nigra in ventricular coordinates, Brain Res. Bull. 14 (1985) 349-367.
17. K. Frey, M. Kilbourn, T. Robinson, Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine, Eur. J. Pharmacol. 334 (1997) 273-279.
18. S. Friedman, E. Castaaneda, G. Hodge, Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity, Pharmacol. Biochem. Behav. 61 (1998) 35-44.
19. F. Fumagalli, R.R. Gainetdinov, K.J. Valenzano, M.G. Caron, Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter, J. Neurosci. 18 (1998) 4861-4869.
20. D. Gash, C.M. Kearns, GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo, Brain Res. 672 (1995) 104-111.
21. M. Gordon, W. Schreier, X. Ou, L. Holcomb, D. Morgan, Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat, J. Comp. Neurol. 388 (1997) 106-119.
22. H.J.G. Gundersen, P. Bagger, T.F. Bendtsen, S.M. Evans, L. Korbo, N. Marcussen, A. Moller, K. Nielsen, J.R. Nyengaard, B. Pakkenberg, F.B. Sorensen, A. Vesterby, M.J. West, The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis, APMIS 96 (1988) 857-881.
23. G.M. Halliday, I. Tork, Comparative anatomy of the ventromedial mesencephalic tegmentum in the rat, cat, monkey and human, J. Comp. Neurol. 252 (1986) 423-445.
24. R. Hassler, Zur Pathologie der Paralysis Agitans und des post-enzephalitischen Parkinsonismus, J. Psychol. Neurol. 48 (1938) 387-476.
25. T. Hastings, D. Lewis, M. Zigmond, Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections, Proc. Natl. Acad. Sci. USA 93 (1996) 1956-1961.
26. H. Hirata, J.L. Cadet, p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies, J. Neurochem. 69 (1997) 780-790.
27. M. Laruelle, R.J. Iyer, M.S. Al-Tikriti, Y. Zea-Ponce, R. Malison, S.S. Zoghbi, R.M. Baldwin, H.F. Kung, D.S. Charney, P.B. Hoffer, R.B. Innis, C.W. Bradberry, Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates, Synapse 25 (1997) 1-14.
28. M. LaVoie, T. Hastings, Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine, J. Neurosci. 19 (1999) 1484-1491.
29. J.C. Linder, S.J. Young, P.M. Groves, Electron microscopic evidence for neurotoxicity in the basal ganglia, Neurochem. Int. 26 (1995) 195-202.
30. Y. Liu, R. Edwards, The role of vesicular transport proteins in synaptic transmission and neural degeneration, Ann. Rev. Neurosci. 20 (1997) 125-156.
31. G. Marek, G. Vosmer, L. Seiden, The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat, Brain Res. 516 (1990) 1-7.
32. U.D. McCann, D.F. Wong, F. Yokoi, V. Villemagne, R.F. Dannals, G.A. Ricaurte, Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [C-11]WIN-35,428, J. Neurosci. 18 (1998) 8417-8422.
33. D.A. McRitchie, C.D. Hardman, G.M. Halliday, Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans, J. Comp. Neurol. 364 (1996) 121-150.
34. W. Melega, G. Lacan, A. DeSalles, M. Phelps, Long term methamphetamine-induced decreases of [11C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey, Synapse 35 (2000) 243-249.
35. W. Melega, G. Lacan, D. Harvey, S. Huang, M. Phelps, Dizocilpine and reduced body temperature do not prevent methamphetamineinduced neurotoxicity in the vervet monkey: [11C]WIN-35,428-positron emission tomography studies, Neurosci. Lett. 258 (1998) 17-20.
36. 18F]Fluoro-L-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys, Synapse 22 (1996) 63-69.
37. W.P. Melega, M.J. Raleigh, D.B. Stout, G. Lacan, S.C. Huang, M.E. Phelps, Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey, Brain Res. 766 (1997) 113-120.
38. L. Naudon, R. Raisman-Vozari, R. Edwards, I. Leroux-Nicollet, D. Peter, Y. Liu, J. Costentin, Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenzine binding sites, Eur. J. Neurosci. 8 (1996) 842-846.
39. W.T. Norton, D.A. Aquino, I. Hozumi, F.C. Chiu, C.F. Brosnan, Quantitative aspects of reactive gliosis: a review, Neurochem. Res. 17 (1992) 877-885.
40. E. O'Hearn, G. Battaglia, E. De Souza, M. Kuhar, M. Molliver, Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity, J. Neurosci. 8 (1988) 2788-2803.
41. B. Pakkenberg, H.J.G. Gundersen, Total number of neurons and glial cells in human brain nuclei estimated by the disector and the fractionator, J. Microscopy 150 (1988) 1-20.
42. H. Pakkenberg, B. Andersen, R. Burns, B. Pakkenberg, A stereological study of substantia nigra in young and old rhesus monkeys, Brain Res. 693 (1995) 201-206.
43. A. Parent, B. Lavoie, The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys, Adv. Neurobiol. 60 (1993) 25-33.
44. C. Patlak, R. Blasberg, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations, J. Cereb. Blood Flow Metab. 5 (1985) 584-590.
45. C. Patlak, R. Blasberg, J. Fenstermacher, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data, J. Cereb. Blood Flow Metab. 3 (1983) 1-7.
46. C. Pu, C. Vorhees, Developmental dissociation of methamphetamineinduced depletion of dopaminergic terminal and astrocyte reaction in rat striatum, Dev. Brain Res. 72 (1993) 325-328.
47. G.A. Ricaurte, R.W. Guillery, L.S. Seiden, C.R. Schuster, R.Y. Moore, Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain, Brain Res. 235 (1982) 93-103.
48. G.A. Ricaurte, U.D. McCann, Neurotoxic amphetamine analogues: effects in monkeys and implications for humans, Ann. NY Acad. Sci. 648 (1992) 371-382.
49. G.A. Ricaurte, C.R. Schuster, L.S. Seiden, Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study, Brain Res. 193 (1980) 153-163.
50. T. Robinson, J. Becker, Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis, Brain Res. Rev. 11 (1986) 157-198.
51. T. Robinson, Z. Mocsary, D. Camp, I. Whishaw, Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system, J. Neurosci. 14 (1994) 2687-2696.
52. T. Robinson, J. Yew, P. Paulson, D. Camp, The long-term effects of neurotoxic doses of methamphetamine on the extracellular concentration of dopamine measured with microdialysis in striatum, Neurosci. Lett. 110 (1990) 193-198.
53. L.J. Ryan, J.C. Linder, M.E. Martone, P.M. Groves, Histological and ultrastructural evidence that d-amphetamine causes degeneration in neostriatum and frontal cortex of rats, Brain Res. 518 (1990) 67-77.
54. L.S. Seiden, M.W. Fischman, C.R. Schuster, Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys, Drug Alcohol Depend. 1 (1976) 215-219.
55. L.S. Seiden, G.A. Ricaurte, Neurotoxicity of methamphetamine and related drugs, in: H.Y Metzler (Ed.), Psychopharmacology: the Third Generation of Progress, Raven Press, New York, 1987, pp. 359-366.
56. W. Slikker Jr., S.F. Ali, A.C. Scallet, C.H. Frith, G.D. Newport, J.R. Bailey, Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA), Toxicol. Appl. Pharmacol. 94 (1988) 448-457.
57. P.K. Sonsalla, N.D. Jochnowitz, G.D. Zeevalk, J.A. Oostveen, E.D. Hall, Treatment of mice with methamphetamine produces cell loss in the substantia nigra, Brain Res. 738 (1996) 172-175.
58. L. Steranka, E. Sanders-Bush, Long-term effects of continuous exposure to amphetamine on brain dopamine concentration and synaptosomal uptake in mice, Eur. J. Pharmacol. 65 (1980) 439-442.
59. R. Switzer, Strategies for assessing neurotoxicity, Neurosci. Biobehav. Rev. 15 (1991) 89-93.
60. D.M. Togasaki, Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine, Neuroscience 67 (1995) 631-647.
61. M. Trulson, M. Cannon, T. Faegg, J. Raese, Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: tyrosine hydroxylase immunochemistry and quantitative light microscopic studies, Brain Res. Bull. 15 (1985) 569-577.
62. T. Vander Borght, M. Kilbourn, T. Desmond, D. Kühl, K. Frey, The vesicular monoamine transporter is not regulated by dopaminergic drug treatments, Eur. J. Pharmacol. 294 (1995) 577-583.
63. V. Villemagne, J. Yuan, D. Wong, R. Dannals, G. Hatzidimitriou, W. Mathews, H. Ravert, J. Musachio, U. McCann, G. Ricaurte, Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations, J. Neurosci. 18 (1998) 419-427.
64. N. Volkow, L. Chang, G. Wang, J. Fowler, D. Franceschi, S. Gatley, C. Wong, R. Hitzemann, N. Pappas, In vivo evidence that methamphetamine abuse produces long lasting changes in dopamine transporters in human brain, J. Nucl. Med. 40 (1999) 110 P.
65. G. Wagner, G. Ricaurte, C. Johanson, C. Schuster, L. Seiden, Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate, Neurology 30 (1980) 547-550.
66. G.C. Wagner, G.A. Ricaurte, L.S. Seiden, C.R. Schuster, R.J. Miller, J. Westley, Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine, Brain Res. 181 (1980) 151-160.
67. M. West, New stereological methods for counting neurons, Neurobiol. Aging 14 (1993) 275-285.
68. M.J. West, L. Slomianka, H.J.G. Gundersen, Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator, Anat. Rec. 231 (1991) 482-497.
69. J. Wilson, K. Kalasinsky, A. Levey, C. Bergeron, G. Reiber, R. Anthony, G. Schmunk, K. Shannak, J. Haycock, S. Kish, Striatal dopamine nerve terminal markers in human, chronic methamphetamine users, Nature Med. 2 (1996) 699-703.
70. M. Wilson, M. Molliver, Microglial response to degeneration of serotonergic axon terminals, Glia 11 (1994) 18-34.
71. W.L. Woolverton, G.A. Ricaurte, L.S. Forno, L.S. Seiden, Long-term effects of chronic methamphetamine administration in rhesus monkeys, Brain Res. 486 (1989) 73-78.
72. Y. Zhang, J.A. Angulo, Contrasting effects of repeated treatment vs. withdrawal of methamphetamine on tyrosine hydroxylase messenger RNA levels in the ventral tegmental area and substantia nigra zona compacta of the rat brain, Synapse 24 (1996) 218-223.